Chronic kidney disease (CKD), which nearly doubled as a cause of death worldwide between 1990 and 2010 and was the 18th highest cause of death around the world in 2010, 1 is a common health problem with increasing incidence and prevalence, high costs and poor consequences. 
The most important established risk factors for CKD are diabetes and hypertension. 6, 7 In addition, recently some observational studies have suggested that CKD may be a renal phenotype of metabolic syndrome (MetS). 8 MetS is a common worldwide disorder, which is characterised by a cluster of metabolic abnormalities including abdominal obesity, elevated triglyceride level, low high-density lipoprotein (HDL) cholesterol level, hypertension and high fasting glucose level. 9, 10 It has become a major public health problem in several countries and represents a common clinical condition in countries with a high incidence of obesity and western dietary pattern. 11 The risk of renal insufficiency in individuals with
MetS might be associated with the presence of hypertension and hyperglycaemia. However, some data suggest that MetS is an independent cause of CKD. 7, 12, 13 Nevertheless, there are still some discrepancies regarding the role of each single part of metabolic syndrome on CKD risk, and whether the risk associated with the full syndrome is greater than the sum of its components. Defining the risk conveyed by any single component, as compared with that of the full syndrome, might help to choose the best approach for identifying people at risk for CKD. In this study, we performed a metaanalysis of studies examining the relation of metabolic syndrome to the risk of CKD, giving particular attention to the risk conveyed by each trait of the syndrome.
| ME THODS
The protocol of this meta-analysis was registered in PROSPERO (PROSPERO 2016: CRD42016036158) . This meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement 14 
| Data sources and search strategy
We searched for all published observational studies that described the associations of metabolic syndrome with the risk of chronic kidney disease. Relevant studies were identified by searching MEDLINE, EMBASE, and PubMed databases for all articles pub- A manual search for additional relevant studies using references from retrieved articles was also performed.
| Study's selection criteria
Studies were included in the current meta-analysis if they met Two authors independently performed the study selection and disagreements were resolved by consensus or, when necessary, by the third reviewer. The exclusion criteria were as follows: studies with no relevant exposure or outcome, studies that did not report risk estimate, studies that reported risk estimate for metabolic syndrome components only, studies that investigated transition from early-stage to late-stage CKD, and studies with overlapped subjects, review articles, editorials, comments, conference abstracts and letters.
| Data extraction
After determining the qualified articles, data were extracted according to a standard protocol. To improve accuracy and critical appraisal, data extraction was performed by 2 independent investigators, and disagreements between investigators were resolved by consensus. The following characteristics were extracted from the original studies: name of the first author, study 
| Quality assessment
Study quality was independently evaluated by 2 of the reviewers based on the Newcastle-Ottawa Scale (NOS) for quality assessment of observational studies. 15 The scales allocate stars, a maximum of 9, for quality of selection, comparability, exposure and outcome of study subjects. A final score 7-9 was considered as high quality.
| Statistical analysis
The study-specific maximally adjusted ORs, RRs or HRs were pooled to examine the association of metabolic syndrome and its components with the risk of CKD. Heterogeneity among the studies was estimated using the Cochran Q test and I 2 statistic. 16 I 2 values of 25%, 50%, and 75% correspond to cut-off points for low, moderate and high degrees of heterogeneity, respectively. The risk estimates were pooled using the random-effects model (DerSimonian-Laird approach) 17 because of anticipated statistical heterogeneity. Before commencement of the analysis, prespecified subgroups were designated to stratify studies according to participant-specific characteristics such as gender, diabetes status and race, and study-specific characteristics such as study design (cohort or cross-sectional) and the definitions used for metabolic syndrome. Moreover, sensitivity analyses were conducted to evaluate the influence of studies, which differed in certain characteristics from the others. Publication bias was estimated using the Egger and Begg tests for funnel plot asymmetry. 18, 19 All statistical tests for the present meta-analysis were done by stata (version 14.0; Stata Corporation, College Station, TX, USA).
| RE SULTS

| Study characteristics
A total of 4642 studies were identified by the initial literature search. The flow diagram describing the detailed process of screening and excluded studies with specific reasons is displayed in Figure 1 . The primary eligibility process yielded 63 studies 8, 9, 12, 
| Overall analysis of pooled data
The association between MetS and CKD risk was investigated in 66 studies, 8, 9, 12, involving a total of 699 065 CKD patients and 11 109 003 participants. The pooled risk estimates and heterogeneity tests for the overall and subgroup analyses are presented in Table 2 . The presence of metabolic syndrome was associated with a significant 50% increased risk of CKD (OR = 1.50, 95% CI = 1.43-1.56), with evidence of moderate heterogeneity across studies (I 2 = 72.3%, P < .001). The strength and direction of this association was found to be similar in prospective cohort and cross-sectional studies ( Figure 2 and Table 2 
| MetS components and chronic kidney disease
| Increased blood glucose
There were 42 studies Additional subgroup analysis by ethnicity and sex showed a significant association between impaired fasting glucose and CKD risk in different ethnicities and sex groups ( Table 2 ). Performing sensitivity analysis by excluding studies with unadjusted estimates resulted in similar overall pooled OR for participants with increased blood glucose (OR = 1.37, 95% CI = 1.24-1.50).
| Elevated blood pressure
There were 44 studies . In the analysis stratified by sex and study type, the association between elevated blood pressure and CKD risk was significant in different subgroups. This increased risk was independent of diabetes status, although diabetic subjects with increased blood pressure had a higher CKD risk than non-diabetic subjects with increased blood pressure ( Table 2 ). After the exclusion of studies that adjusted the risk estimate for none of the potential confounders, the overall risk was equal to the original estimate (OR = 1.37, 95% CI = 1.28-1.46).
| Increased triglycerides
The risk of CKD associated with increased triglycerides levels was reported in 46 studies, participants. The pooled analysis of all these studies showed that patients with high triglyceride levels had a higher overall risk of CKD (OR = 1.28, 95% CI = 1.20-1.36), with significant between-study heterogeneity (I 2 = 97.4%, P ˂ .001). In the analysis stratified by ethnicity, sex, and study type, the association F I G U R E 2 Forest plot showing overall and subgroup analysis by study type on the association between metabolic syndrome and risk of CKD F I G U R E 3 Forest plot showing overall and subgroup analysis by criteria used for obesity assessment on the association between obesity and risk of CKD between high triglyceride levels and CKD risk was significant in different subgroups. This increased risk was independent of diabetes status, but no considerable difference in CKD risk was observed between diabetic and non-diabetic patients with elevated blood pressure (Table 2 ). In the sensitivity analysis, we excluded the studies with crude risk estimates and observed that the pooled OR was not considerably changed (OR = 1.29, 95% CI = 1.21-1.37).
| Obesity
The evaluation of the association between obesity and risk of CKD was reported in 47 studies 9,12,21,23,24,26-28, 33-36,38-40,42-45,47,48,51-65,67,69,71-76,79,82,83 with a total of 694 600 patients and 11 054 459 participants. Of this, 12 studies assessed obesity based on body mass index (BMI), 9, 28, 36, 43, 45, 56, 65, 71, 72, 76, 79 ,83 and 35 studies used waist circumference for the assessment of obesity. 12, 21, 23, 24, 26, 27, [33] [34] [35] [38] [39] [40] 42, 44, 47, 48, [51] [52] [53] [54] [55] [57] [58] [59] [60] [61] [62] [63] [64] 67, 69, [73] [74] [75] 82 The overall CKD risk related to higher BMI/waist circumference, as compared with lower BMI/waist circumference, was 1.22 (95% CI = 1.12-1.31), and was greater for higher values of waist circumference than BMI (Figure 3 ). In the stratified analysis by ethnicity, sex, and study type, the increased risk associated with higher values of BMI/waist circumference was significant in different subgroups. The relationship between obesity and CKD was a diabetes-dependent association. While diabetic patients with increased BMI/waist circumference had a significant 51% increased risk of CKD, non-diabetic subjects had a non-significant increased risk (Table 2 ). When the results of studies which were based on crude estimates were excluded from the analysis, the pooled ORs did not substantially change (OR = 1.20, 95% CI = 1.10-1.30).
| Reduced HDL-cholesterol
The relationship between HDL-cholesterol level and CKD risk was examined in 45 studies, lower values of HDL-cholesterol had a significant 15% increased risk of CKD, non-diabetic subjects had a non-significant increased risk (Table 2) . After the exclusion of articles that adjusted the odds ratio for none of the confounders, the pooled risk was equal to the original estimate (OR = 1.20, 95% CI = 1.11-1.29).
| The comparison of the overall odds ratio of CKD associated with the presence of metabolic syndrome, its individual components and the number of metabolic syndrome components
The pooled risk estimates of CKD for MetS, its individual component and the number of components of MetS are presented in Figure 4 .
Metabolic syndrome and all of its 5 components were significantly associated with the risk of CKD. Among the components of the syndrome, increased fasting glucose and elevated blood pressure were the most important risk factors. The overall odds ratio of each component of the syndrome was lower than those obtained for the full syndrome in the same studies. We further evaluated whether
Comparison of the overall risk of CKD conveyed by the metabolic syndrome, its individual components and the number of metabolic syndrome components the relationship between the MetS and CKD was associated with the number of MetS traits and found a significant graded trend between increasing number of metabolic syndrome traits and CKD risk (Table 2 and Figure 4 ).
| Evaluation of publication bias
No evidence of publication bias was detected for most associations in visual inspection of the funnel plot or by the Egger's and Begg's tests. In the overall analyses, possible publication bias on the Egger's linear regression test was only observed for studies that had examined the association of increased triglycerides (t = 2.65, P = .011), obesity (t = 2.39, P = .021) and reduced HDL-cholesterol (t = 3.40, P = .001) with the risk of CKD (Table 2 ).
| D ISCUSS I ON
Recently, the role of metabolic syndrome and its components in CKD has been examined extensively; although, the results are inconclu- [91] [92] [93] [94] In addition, there is emerging evidence that alterations in the production of adipose tissue-derived adipokines and cytokines may also be involved in the pathogenesis of CKD among obese patients. 95 The main strength of the present study is its large pooled sample size, enabling the determination of robust estimates for the relationship of the MetS and its single components to CKD disease in deferent subgroups that could not be estimated exactly in single studies.
This meta-analysis compared the risk conveyed by any single component of MetS with that of the full syndrome, which might help to choose the best approach for identifying individuals at risk of CKD.
In addition, this is the first meta-analysis examining the risk of CKD among patients with MetS according to diabetes status and different definitions of metabolic syndrome. Nevertheless, some limitations of this meta-analysis need to be discussed. First, significant heterogeneity was evident in most analyses, which limited the interpretation of our findings. Subgroup analyses by various definitions of MetS, study design, sex and ethnicity of the participants were performed to detect the potential source of heterogeneity, and revealed that sex could explain part of observed heterogeneity. In addition to the mentioned reason, the studies also differed in type and extent of statistical adjustment for confounders and inclusion and exclusion criteria, which may, to some extent, result in between-study heterogeneity. Secondly, some included studies used a cross-sectional design, which is more prone to selection and recall bias than a cohort design. However, except for the analysis of fasting blood glucose, in all other analyses, both prospective cohort and cross-sectional studies yielded similar results, showing that our findings are reliable.
Third, studies investigating the relationship between MetS and CKD risk used different cut-off points for its components, which complicate comparisons between studies. Fourth, despite best efforts to perform a comprehensive search, a significant evidence for publication bias was detected for studies that had examined the association of increased triglycerides, obesity, and reduced HDL-cholesterol with the risk of CKD. The present meta-analysis analysed only on studies with English language and those that published in other languages may be the source of publication bias.
In summary, the present meta-analysis of the available evidence Therefore, early detection, management and eventually prevention of the metabolic syndrome and its individual components should become an important approach for the reduction of CKD burden in diabetic, in non-diabetic and in the general population.
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